GlaxoSmithKline's Experimental Shingles Vaccine Hits Goal In Late-Stage Study

GSK today announced that a pivotal phase III study to assess the efficacy of HZ/su, an investigational vaccine for the prevention of shingles, has met its primary endpoint. Analysis of the primary endpoint showed that HZ/su reduced the risk of shingles by 97.2 per cent in adults aged 50 years and older compared to placebo.

http://ift.tt/1z0MkTR